Angiotensin receptor blockers (ARBs) are often used as first-line therapy for the treatment of systemic hypertension because of their perceived efficacy and relatively low incidence of adverse effects.
The FDA has approved a third long-acting, once-weekly, glucagon-like peptide (GLP-1) receptor agonist for the treatment of type 2 diabetes mellitus, joining exenetide ER and albiglutide. Dulaglutide is made up of two identical human-based GLP-1 analogs linked to a modified human IgG4 Fc fragment. This makes the molecule resistant to degradation by DPP-4, slows absorption, reduces renal clearance, and extends the elimination half-life to approximately 5 days. Dulaglutide is marketed by Eli Lilly as Trulicity.